Stroke Mechanism Evolution in Intracranial Atherosclerotic Stenosis

NCT ID: NCT02705599

Last Updated: 2023-04-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 230 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-08-31
• Study Completion Date: 2020-12-31

Brief Summary

Predictors of the risk of recurrent stroke for patients with symptomatic intracranial atherosclerotic stenosis (ICAS) remain unknown. The study will be to explore the stroke mechanism evolution in patients with ICAS by multi-model magnetic resonance imaging (MRI) which consists of diffusion-weighted imaging (DWI) and high-resolution MRI (HRMRI). The patients with symptomatic ICAS will undergo multi-model MRI. The baseline data, infarct patterns on DWI, and plaque features on HRMRI will be collected. The stroke mechanisms will be determined by the infarct patterns. During the 2 years follow-up, the recurrent ischemic events will be recorded. By comparing the baseline data, infarct patterns, and plaque features in patients with and without recurrent strokes, the high-risk features of patients with symptomatic ICAS will be identified. The evaluation of stroke mechanisms of patients with symptomatic ICAS will be summarized.

Detailed Description

Objective:

Primary objective: to identify which plaque features on HRMRI in patients with symptomatic ICAS are related to recurrent stroke.

Secondary objectives: To compare plaque features in subgroups.

Patients enrollment please see Eligibility part.

Methods:

A 3T GE (DISCOVERY MR 750, GE Healthcare, Waukesha, WI, USA) and a 3T Siemens Trio MR scanner (Siemens Healthcare, Ehrlangen, Germany) will be used in this study. The multiple sequences will include 3D time of flight (TOF) MR angiography, 3D T1-weighted imaging, proton attenuation weighted imaging, magnetization-prepared rapid acquisition with gradient-echo sequence (MPRAGE), and contrast enhancement on T1-weighted imaging.

The parameters of multiple sequences on GE MR Scanner are followed. 3D TOF: repetition time (TR) = minimum, echo time (TE) = minimum; field of view (FOV) = 240×220 mm2, matrix = 288×192, slice thickness = 2 mm, flip angle (FA) = 20, and scan time = 1:53 minutes. 3D CUBE T1: TR = 600 ms, TE = minimum, FOV = 240×220 mm2, matrix = 480×480, slice thickness = 0.8 mm, FA = NA, and scan time = 3:33 minutes. 3D CUBE PD: TR = 1500 ms, TE = 40 ms, FOV = 240×220 mm2, matrix = 384×384, slice thickness = 0.8 mm, FA = NA, and scan time = 2:40 minutes. MP RAGE: TR = minimum, TE = 3.3 ms, FOV = 240×240 mm2, matrix = 256×256, slice thickness = 0.8 mm, FA = 12, and scan time = 2:18 minutes.

The parameters of multiple sequences on Siemens MR Scanner are followed. 3D TOF: TR= 24 ms, TE = 4.32 ms; FOV = 140×140 mm2, matrix = 256×256, slice thickness = 0.9 mm, FA = 18, and scan time = 2 min 14 s. 3D SPACE T1: TR = 800 ms, TE = 22 ms, FOV = 180×168 mm2, matrix = 256×251, slice thickness = 0.8 mm, FA = NA, and scan time = 4:4 minutes. 3D SPACE PD: TR = 1700 ms, TE = 23 ms, FOV = 180×180 mm2, matrix = 320×304, slice thickness = 0.6 mm, FA = NA, and scan time = 4:25 minutes. MP RAGE: TR = 776.13 ms, TE = 5.8 ms, FOV = 144×144 mm2, matrix = 240×240, slice thickness = 1 mm, FA = 15, and scan time = 2:39 minutes.

IMAGING EVALUATION In this study, plaques will be identified as focal or diffuse but eccentric wall thickenings compared with normal vessel wall.

Plaque composition will include hemorrhage and calcification. The anatomical location of plaque will be recorded as either one of the four quadrants of the vessel wall on cross-sectional images.

Plaque that is distributed across ≥3 quadrants of the lumen perimeter will be defined as diffuse and that involving ≤2 will be defined as focal.

In this study, enhancement analysis will include both grades and patterns. Enhancement will be classified into 3 different grades: non-enhancement, mild-moderate enhancement, and strong enhancement. Mild-moderate enhancement is defined as less than that of the pituitary infundibulum. Strong enhancement is equal to or stronger than that of the pituitary infundibulum. The pattern of enhancement will be categorized as focal, heterogeneous, or homogenous.

The vessel and wall areas at the maximal lumen narrowing (MLN) site will be measured. The plaque volume will be calculated as the product of the plaque area and the thickness of the slices containing the plaque. The plaque/wall ratio was defined as the plaque area divided by wall area ×100%. The remodeling index was calculated as the ratio of the vessel area at the MLN site to that at the reference site. The reference site was selected based on the Warfarin-Aspirin Symptomatic Intracranial Disease trial method.

STROKE MECHANISMS The stroke includes hypoperfusion, perforator (branch atheromatous disease), artery-to-artery embolism, or co-existing (combinations of these ischemic mechanisms).

FOLLOW-UP At the 2 years follow-up, patients were contacted monthly by phone to determine whether any events had occurred at the first year and three months at the second year. Every three months, patients were examined face-to-face by two neurologists at the first year and every six months at the second year. The follow-up information included transient ischemic attack and ischemic stroke (in any vascular territory), brain hemorrhage, and all-cause death. If these events but death suspected, patients underwent brain computed tomography or MR imaging.

Conditions

Stroke

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Exclusion Criteria

• Non-atherosclerosis vasculopathy such as vasculitis and arterial dissection diagnosed by comprehensive laboratory work (such as erythrocyte sedimentation rate or C-reactive protein elevations, antinuclear antibody, or antiphospholipid antibody positivity), vascular imaging, and clinical evaluation;
• Contraindication to MR examination, medical instability precluding MR examination.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Tiantan Hospital

OTHER

Sponsor Role: collaborator

Chinese PLA General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Xin Lou

Deputy Chief

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xin Lou, M.D. Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Chinese PLA General Hospital

Ning Ma, M.D. Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Beijing Tiantan Hospital

Locations

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Beijing Tiantan Hospital

Beijing, , China

Countries

China

References

Lyu J, Ma N, Liebeskind DS, Wang DJ, Ma L, Xu Y, Wang T, Miao Z, Lou X. Arterial Spin Labeling Magnetic Resonance Imaging Estimation of Antegrade and Collateral Flow in Unilateral Middle Cerebral Artery Stenosis. Stroke. 2016 Feb;47(2):428-33. doi: 10.1161/STROKEAHA.115.011057. Epub 2016 Jan 5.

Reference Type: BACKGROUND

PMID: 26732570 (View on PubMed)

Ma N, Jiang WJ, Lou X, Ma L, Du B, Cai JF, Zhao TQ. Arterial remodeling of advanced basilar atherosclerosis: a 3-tesla MRI study. Neurology. 2010 Jul 20;75(3):253-8. doi: 10.1212/WNL.0b013e3181e8e714.

Reference Type: BACKGROUND

PMID: 20644151 (View on PubMed)

Lopez-Cancio E, Matheus MG, Romano JG, Liebeskind DS, Prabhakaran S, Turan TN, Cotsonis GA, Lynn MJ, Rumboldt Z, Chimowitz MI. Infarct patterns, collaterals and likely causative mechanisms of stroke in symptomatic intracranial atherosclerosis. Cerebrovasc Dis. 2014;37(6):417-22. doi: 10.1159/000362922. Epub 2014 Jul 4.

Reference Type: BACKGROUND

PMID: 25011483 (View on PubMed)

Hou Z, Li M, Lyu J, Xu Z, Liu Y, He J, Jing J, Wang R, Wang Y, Lou X, Miao Z, Ma N. Intraplaque Enhancement Is Associated With Artery-to-Artery Embolism in Symptomatic Vertebrobasilar Atherosclerotic Diseases. Front Neurol. 2021 Sep 1;12:680827. doi: 10.3389/fneur.2021.680827. eCollection 2021.

Reference Type: DERIVED

PMID: 34539546 (View on PubMed)

Yang M, Ma N, Liu L, Wang A, Jing J, Hou Z, Liu Y, Lou X, Miao Z, Wang Y. Intracranial collaterals and arterial wall features in severe symptomatic vertebrobasilar stenosis. Neurol Res. 2020 Aug;42(8):649-656. doi: 10.1080/01616412.2020.1782081. Epub 2020 Jun 23.

Reference Type: DERIVED

PMID: 32573371 (View on PubMed)

Xu Z, Li M, Lyu J, Hou Z, He J, Mo D, Gao F, Liu X, Sui B, Shen M, Pan Y, Wang Y, Lou X, Miao Z, Luo B, Ma N. Different risk factors in identical features of intracranial atherosclerosis plaques in the posterior and anterior circulation in high-resolution MRI. Ther Adv Neurol Disord. 2020 Mar 13;13:1756286420909991. doi: 10.1177/1756286420909991. eCollection 2020.

Reference Type: DERIVED

PMID: 32206091 (View on PubMed)

Xu Z, Li M, Hou Z, Lyu J, Zhang N, Lou X, Miao Z, Ma N. Association between basilar artery configuration and Vessel Wall features: a prospective high-resolution magnetic resonance imaging study. BMC Med Imaging. 2019 Dec 26;19(1):99. doi: 10.1186/s12880-019-0388-3.

Reference Type: DERIVED

PMID: 31878890 (View on PubMed)

Ma N, Xu Z, Lyu J, Li M, Hou Z, Liu Y, Yang M, Mo D, Gao F, Song L, Sun X, Liu L, Liu X, Sui B, Shen M, Ma L, Wang Y, Wang Y, Miao Z, Lou X. Association of Perforator Stroke After Basilar Artery Stenting With Negative Remodeling. Stroke. 2019 Mar;50(3):745-749. doi: 10.1161/STROKEAHA.118.023838.

Reference Type: DERIVED

PMID: 30661491 (View on PubMed)

Other Identifiers

HRMRI-NM-Tiantan

Identifier Type: -

Identifier Source: org_study_id